AcelRx Pharma (ACRX) Tops Q2 EPS by 6c

AcelRx Pharma (NASDAQ: ACRX) reported Q2 EPS of ($0.20), $0.06 better than the analyst estimate of ($0.26).

"The positive opinion and recommendation for approval of Zalviso by the CHMP is an important step towards approval by the EC. In the U.S., we have a meeting scheduled with the FDA to work towards determining a regulatory path forward," commented Howie Rosen, interim chief executive officer of AcelRx. "Lastly, we look forward to the top-line data from the SAP301 Phase 3 study of ARX-04. ARX-04 represents a significant opportunity for AcelRx and has the potential to be the first sublingual, high-potency opioid for use in non-opioid tolerant patients."

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c